Selected article for: "cold symptom and flu cold symptom"

Author: Lim, Jong-Min; Do, Eunju; Park, Dong-Chan; Jung, Go-Woon; Cho, Hyung-Rae; Lee, Seo-Young; Shin, Jae Wook; Baek, Kyung Min; Choi, Jae-Suk
Title: Ingestion of Exopolymers from Aureobasidium pullulans Reduces the Duration of Cold and Flu Symptoms: A Randomized, Placebo-Controlled Intervention Study
  • Cord-id: ktet18wl
  • Document date: 2018_5_30
  • ID: ktet18wl
    Snippet: AIM: The objective of the study was to assess the efficacy of exopolymers from Aureobasidium pullulans (EAP) on the incidence of colds and flu in healthy adults. METHODS: We conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 76 subjects (30–70 years of age) were recruited from the general population. The subjects were instructed to take one capsule per day of either EAP or a placebo for a period of 8 weeks. The duration of cold and f
    Document: AIM: The objective of the study was to assess the efficacy of exopolymers from Aureobasidium pullulans (EAP) on the incidence of colds and flu in healthy adults. METHODS: We conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 76 subjects (30–70 years of age) were recruited from the general population. The subjects were instructed to take one capsule per day of either EAP or a placebo for a period of 8 weeks. The duration of cold and flu symptoms, a primary variable in assessing effectiveness, and serum cytokine levels as well as WBC counts as secondary variables were also evaluated. RESULTS: EAP was associated with a statistically significant decrease in the duration of cold and flu symptoms, a primary variable in assessing effectiveness. Although cold and flu symptom levels were not significantly different at a significance level of 5%, the cold and flu symptom levels of the EAP group were less severe compared to the placebo group. No statistically significant changes of serum cytokine levels as well as WBC counts were observed. CONCLUSION: The results showed that EAP is a useful pharmaceutical and functional food material for preventing and treating colds and flu.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute reaction: 1, 2
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and additional day: 1, 2
    • abdominal pain diarrhea and abnormally high: 1
    • abdominal pain diarrhea and acute reaction: 1
    • abdominal pain diarrhea and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain diarrhea vomiting and abnormally high: 1
    • abdominal pain diarrhea vomiting and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain diarrhea vomiting nausea and abnormally high: 1
    • abdominal pain diarrhea vomiting nausea and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abnormal change and acute respiratory syndrome: 1
    • abnormal value and acute respiratory syndrome: 1, 2, 3
    • abnormally high and acute respiratory syndrome: 1, 2, 3, 4
    • acid bacteria and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activation state and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • actual recorded and acute respiratory syndrome: 1
    • acute reaction and additional day: 1
    • acute respiratory syndrome and additional day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and adjuvant effect: 1, 2, 3, 4, 5